Loading
A Singapore study of up to 15,000 people developing Mirxes' blood test for nine cancers using microRNA, DNA methylation and proteins.
Project CADENCE (NCT05633342) is an observational study sponsored by MiRXES Pte Ltd. It develops and validates blood-based multi-cancer screening tests through a multi-omic approach combining microRNA, DNA methylation, RNA and protein markers.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 20 March 2023), with an estimated 15,000 participants, a start on 7 July 2022 and primary completion expected in December 2024.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/